艾昆纬-处方集控制对五个慢性病治疗领域商业保险患者的影响（英）-2025

2025-08保险12免费

📄 文件全名: 《艾昆纬-处方集控制对五个慢性病治疗领域商业保险患者的影响（英）-2025-12页.pdf》
🎯 适合读者: 投资人行业研究员
📊 核心数据: • Over 75% of commercially insured patients were initially denied coverage when attempting to fill a new
prescription across the five therapeutic areas analyzed. More than 90% of patients were initially denied in four
delays exceeding three to five weeks, depending on therapeutic area. Between 17% and 31% of patients
• Between 64% and 82% of patients who did not overcome their initial payer rejection within a year failed to
🏷️ 核心议题: #保险

📦 本报告属于月份合集

购买后将获得「2025 年 8 月报告合集」 · 共 3951 份报告打包下载链接

点击获取云盘下载链接

报告摘要

The Impact of Formulary Controls on Commercially Insured Patients in Five Chronic Therapeutic Areas

❓ 常见问题

《艾昆纬-处方集控制对五个慢性病治疗领域商业保险患者的影响（英）-2025》主要包含哪些内容?

The Impact of Formulary Controls on Commercially Insured Patients in Five Chronic Therapeutic Areas核心数据:• Over 75% of commercially insured patients were initially denied coverage when attempting to fill a new;prescription across the five therapeutic areas analyzed. More than 90% of patients were initially denied in four;delays exceeding three to five weeks, depending on therapeutic area. Between 17% and 31% of patients。

这份报告覆盖哪一年、篇幅多大?

覆盖 2025 年,全文约 12。

这份报告是免费的吗?如何获取?

本报告免费查阅,登录资料宝后即可在线获取完整内容。

这份报告适合哪些读者?

适合投资人、行业研究员等读者参考。

报告涉及哪些关键议题?

重点分析了保险等议题。